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In today's world of easy access to the written word, it is all too simple to read widely but fail to interpret correctly or to absorb much of what has been read. The Second Winter Virology Meeting, held in Zermatt in December 1994, represented a very successful strategy to enable the intensive discussion of several Wthe key issues in antiviral chemotherapy and to dige$f, understand and remember the important points. By spending 3 days in a rather remote location, a small group of scientists and clinicians were given the unusual opportunity to stand back from the daily close contact with their particular fields and to discuss in great depth the particular issues on the agenda.
The topics covered at the meeting included the ever increasing concern about the relative costs of the various methods of treatment available; the rapidly changing trends in genital herpes; the special problems associated with herpesvirus infections in immunocompromised patients; the history and future prospects for herpes drug resistance; and a consideration of the possible role of herpesviruses in the progression of AIDS. The new prodrug of penciclovir (famciclovir) and the L-valine ester of aciclovir (valaciclovir), two agents with improved oral bioavailability for the anti-herpesvirus compounds, were much talked about throughout the meeting. As was to be expected, many questions and much discussion concerned the new possibilities afforded by these compounds, the differences in their modes of action, and the implications for their long-term safety.
The declared emphasis throughout the workshop sessions was on education and, perhaps, the scientific presentation which best characterized this objective was that concerned with the use of statistics as applied to the design and evaluation of clinical trials. Several of the examples used to illustrate this lecture were, naturally, concerned with the newer forms of antiviral therapy. The design, execution, and interpretation of clinical trials of virus chemotherapy have become extremely complex, and for many of those present a previously dark area will have been illuminated for the first time.
It is an inescapable fact that a meeting cannot be both small, informal and intense and at the same time open to a very large number of delegates. However, the lectures and discussions can be made available more widely by means of published papers. After the First Winter Virology Meeting, held in December 1993, many of the presentations were published in the form of a supplement to Antiviral Chemistry and Chemotherapy. The resulting volume was well received, and we feel that it contains the quintessential points of the meeting. Following the success of the first supplement, those attending the Second Winter Meeting were aware from the outset that the intention was to publish the proceedings of the meeting in the form of a second supplement. However, while the framework of the articles may have been sketched out by the authors before the meeting, the final versions as published benefit from the discussion and development of the ideas that took place during the course of the workshops. The scientific papers which comprise the present issue, therefore, represent informed and well-rehearsed accounts by those individuals, each of whom is a leading expert in his or her field. Among the conventional reviews, there are also two articles that are based on the opposing sides of a debate concerning the role of herpesviruses as possible co-factors in the progression of AIDS. These articles, which represent the arguments in favour and against this concept, not only reflect the spontaneity and enthusiasm of a lively debate but also form two scholarly reviews, both well researched and furnished with extensive and valuable bibliographies.
Thus, while no researchers, let alone clinicians, have time to keep fully up to date with the information explosion, this supplement provides an educative and readily assimilated digest that should be most helpful to those who wish to be informed of some of the important current developments in the management of herpesvirus infections.
